Beranda › Leukemia Biphenotypic Akut › North Carolina › Greenville
Uji klinis Leukemia Biphenotypic Akut di Greenville, NC
4 studi untuk Leukemia Biphenotypic Akut mencari peserta di lokasi sekitar Greenville (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Menerima pesertaFase 2
- East Carolina University, Greenville
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Menerima pesertaFase 3
- East Carolina University, Greenville
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Menerima pesertaFase 1/2
- East Carolina University, Greenville
Registry of Older Patients With Cancer
Menerima pesertaStudi observasional
- East Carolina University, Greenville
Uji klinis Leukemia Biphenotypic Akut di kota lain
- Seattle, WA15 studi
- Houston, TX11 studi
- New York City, NY10 studi
- Atlanta, GA9 studi
- Durham, NC8 studi
- Memphis, TN7 studi
- Chicago, IL7 studi
- Charlotte, NC6 studi
- Baldwin Park, CA6 studi
- Philadelphia, PA6 studi
- Dallas, TX6 studi
- Aurora, CO6 studi
Studi lain di Greenville
- Leukemia Mieloid Akut10 studi
- Penyakit Sel Sabit9 studi
- Purpura Trombositopenik Idiopatik6 studi
- Gagal Jantung6 studi
- Leukemia Limfositik Kronis5 studi
- Limfoma Burkitt5 studi
- Obesitas5 studi
- Diabetes Tipe 25 studi
- Gangguan Darah5 studi
- Kanker (semua jenis)4 studi
- Penyakit Autoimun4 studi
- Neoplasma Mieloproliferatif4 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.